Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast ...

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.